CBIZ (NYSE:CBZ – Get Free Report) updated its FY24 earnings guidance on Tuesday. The company provided earnings per share guidance of $2.64-$2.69 for the period, compared to the consensus earnings per share estimate of $2.52. The company issued revenue guidance of $1.70-$1.73 billion, compared to the consensus revenue estimate of $1.71 billion. CBIZ also updated its FY 2024 guidance to 2.640-2.690 EPS.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on CBZ. Sidoti upgraded shares of CBIZ from a “neutral” rating to a “buy” rating and lifted their price target for the company from $80.00 to $86.00 in a report on Monday, August 12th. StockNews.com lowered shares of CBIZ from a “hold” rating to a “sell” rating in a report on Thursday, September 5th.
Check Out Our Latest Stock Analysis on CBZ
CBIZ Trading Up 7.5 %
CBIZ (NYSE:CBZ – Get Free Report) last issued its earnings results on Thursday, August 1st. The business services provider reported $0.39 EPS for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.29). CBIZ had a net margin of 7.12% and a return on equity of 14.58%. The business had revenue of $420.00 million during the quarter, compared to analysts’ expectations of $430.38 million. During the same period in the prior year, the business posted $0.55 EPS. The business’s revenue was up 5.4% on a year-over-year basis. On average, research analysts predict that CBIZ will post 2.64 EPS for the current fiscal year.
About CBIZ
CBIZ, Inc provides financial, insurance, and advisory services in the United States and Canada. It operates through Financial Services, Benefits and Insurance Services, and National Practices segments. The Financial Services segment offers accounting and tax, financial advisory, valuation, risk and advisory, and government healthcare consulting services.
Further Reading
- Five stocks we like better than CBIZ
- What Does Downgrade Mean in Investing?
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- What is the Euro STOXX 50 Index?
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- Top Biotech Stocks: Exploring Innovation Opportunities
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for CBIZ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CBIZ and related companies with MarketBeat.com's FREE daily email newsletter.